Previous Close | 1.7300 |
Open | 1.8000 |
Bid | 1.7600 x 500 |
Ask | 1.7900 x 800 |
Day's Range | 1.6800 - 1.8200 |
52 Week Range | 1.0250 - 2.3900 |
Volume | |
Avg. Volume | 1,514,181 |
Market Cap | 297.158M |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4300 |
Earnings Date | Mar 28, 2024 - Apr 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.62 |
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 12 - BPL-003 showed a good safety profile and was well-tolerated with no serious adverse events reported - Acute effects resolved on average in less than two hours, highlighting BPL-003’s potential to fit within the
atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion.